Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
SATURN TRIAL |
|
|---|---|
| Problem | Coronary heart disease |
| Format | Double-blinded multi-center RCT |
| Treatment | Rosuvastatin (40mg) |
| Control | Atorvastatin (80mg) |
| Population | 1039 patients |
| Inclusion criteria | Patients 18 to 75 years of age were eligible if they had at least one vessel with 20% stenosis on clinically indicated coronary angiography and a target vessel for imaging with less than 50% obstruction. Patients who had not been treated with a statin in the preceding 4 weeks were required to have an LDL cholesterol level at entry that was higher than 100 mg per deciliter (2.6 mmol per liter); those who had received such treatment were required to have a level higher than 80 mg per deciliter (2.1 mmol per liter). |
| Exclusion criteria | History of intensive lipid-lowering therapy for more than 3 months in the previous year Uncontrolled hypertension, heart failure, renal dysfunction, or liver disease |
| Follow-up | 104 weeks |
| Primary endpoint | Percent atheroma volume (PAV), decreased by 0.99% |
| Secondary endpoint(s) | Normalized total atheroma volume (TAV) |
| Details | . |
| Brief summary: | Rosuvastatin gave better LDL/HDL than atorva, but atheromata unchanged |
| PAPER: Effect of Two Intensive Statin Regimens on Progression of Coronary Disease | |
|---|---|
| Date | 1 Dec 2011 |
| Journal | N Engl J Med. 2011 Dec 1;365(22):2078-87 |
| Information | Rosuvastatin 40mg vs. Atorvastatin 80mg: -Reduced level LDL -Higher level of HDL cholesterol -BUT Similar degree of regression of PAV S/Es: -Higher alanine aminotransferase in atorvastatin group -Higher proteinuria in rosuvastatin -No difference in HbA1c |